Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country
Introduction: The objective of this study was to evaluate the clinical impact PET with 18F-FDG and 11C-PIB in patients with dementia in a developing country.Methodology: Retrospective study of the patients referred for the evaluation of dementia to the only PET center in Uruguay. A total of 248 pati...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-05-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2021.630958/full |
id |
doaj-168719c1498a44aea2c4136259ec8cab |
---|---|
record_format |
Article |
spelling |
doaj-168719c1498a44aea2c4136259ec8cab2021-05-04T05:37:38ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-05-011210.3389/fneur.2021.630958630958Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing CountryAndres Damian0Andres Damian1Fabiola Portugal2Nicolas Niell3Nicolas Niell4Adriana Quagliata5Karina Bayardo6Omar Alonso7Omar Alonso8Rodolfo Ferrando9Rodolfo Ferrando10Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, UruguayCentro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, UruguayCentro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, UruguayCentro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, UruguayCentro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, UruguayCentro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, UruguayCentro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, UruguayCentro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, UruguayCentro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, UruguayCentro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, UruguayCentro de Medicina Nuclear e Imagenología Molecular, Hospital de Clínicas, Universidad de la República (UdelaR), Montevideo, UruguayIntroduction: The objective of this study was to evaluate the clinical impact PET with 18F-FDG and 11C-PIB in patients with dementia in a developing country.Methodology: Retrospective study of the patients referred for the evaluation of dementia to the only PET center in Uruguay. A total of 248 patients were identified, from which 70 patients were included based on the availability of medical history and clinical follow-up. Main outcomes included change in diagnosis, diagnostic dilemma and AD treatment. We evaluated the association of clinical outcomes with PET concordance with baseline diagnosis, diagnostic dilemma, level of education, AD pathology/Non-AD pathology (AD/Non-AD), baseline diagnosis and 11C-PIB PET result.Results: Baseline clinical diagnosis was concordant with 18F-FDG and 11C-PIB PET results in 64.7 and 77.1% of the patients, respectively. Change in diagnosis after PET was identified in 30.0% of the patients and was associated with discordant 18F-FDG (p = 0.002) and 11C-PIB (p < 0.001) PET results, previous diagnostic dilemma (p = 0.005), low education (p = 0.027), Non-AD baseline diagnosis (p = 0.027), and negative 11C-PIB PET result (p < 0.001). Only the last variable remained significant in the multivariate analysis (adjusted p = 0.038). Diagnostic dilemma decreased after PET from 15.7 to 7.1% (p = 0.11) and was associated with Non-AD diagnosis (p = 0.002) and negative 11C-PIB PET result (p = 0.003). Change in AD treatment after PET occurred in 45.7% of the patients.Conclusion:18F-FDG and 11C-PIB PET had a significant clinical impact in terms of change in diagnosis and treatment in patients with dementia in a developing country, similar to that reported in high-income countries.https://www.frontiersin.org/articles/10.3389/fneur.2021.630958/fullPETAlzheimer'samyloiddementianeuroimagingbiomarkers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Andres Damian Andres Damian Fabiola Portugal Nicolas Niell Nicolas Niell Adriana Quagliata Karina Bayardo Omar Alonso Omar Alonso Rodolfo Ferrando Rodolfo Ferrando |
spellingShingle |
Andres Damian Andres Damian Fabiola Portugal Nicolas Niell Nicolas Niell Adriana Quagliata Karina Bayardo Omar Alonso Omar Alonso Rodolfo Ferrando Rodolfo Ferrando Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country Frontiers in Neurology PET Alzheimer's amyloid dementia neuroimaging biomarkers |
author_facet |
Andres Damian Andres Damian Fabiola Portugal Nicolas Niell Nicolas Niell Adriana Quagliata Karina Bayardo Omar Alonso Omar Alonso Rodolfo Ferrando Rodolfo Ferrando |
author_sort |
Andres Damian |
title |
Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country |
title_short |
Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country |
title_full |
Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country |
title_fullStr |
Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country |
title_full_unstemmed |
Clinical Impact of PET With 18F-FDG and 11C-PIB in Patients With Dementia in a Developing Country |
title_sort |
clinical impact of pet with 18f-fdg and 11c-pib in patients with dementia in a developing country |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Neurology |
issn |
1664-2295 |
publishDate |
2021-05-01 |
description |
Introduction: The objective of this study was to evaluate the clinical impact PET with 18F-FDG and 11C-PIB in patients with dementia in a developing country.Methodology: Retrospective study of the patients referred for the evaluation of dementia to the only PET center in Uruguay. A total of 248 patients were identified, from which 70 patients were included based on the availability of medical history and clinical follow-up. Main outcomes included change in diagnosis, diagnostic dilemma and AD treatment. We evaluated the association of clinical outcomes with PET concordance with baseline diagnosis, diagnostic dilemma, level of education, AD pathology/Non-AD pathology (AD/Non-AD), baseline diagnosis and 11C-PIB PET result.Results: Baseline clinical diagnosis was concordant with 18F-FDG and 11C-PIB PET results in 64.7 and 77.1% of the patients, respectively. Change in diagnosis after PET was identified in 30.0% of the patients and was associated with discordant 18F-FDG (p = 0.002) and 11C-PIB (p < 0.001) PET results, previous diagnostic dilemma (p = 0.005), low education (p = 0.027), Non-AD baseline diagnosis (p = 0.027), and negative 11C-PIB PET result (p < 0.001). Only the last variable remained significant in the multivariate analysis (adjusted p = 0.038). Diagnostic dilemma decreased after PET from 15.7 to 7.1% (p = 0.11) and was associated with Non-AD diagnosis (p = 0.002) and negative 11C-PIB PET result (p = 0.003). Change in AD treatment after PET occurred in 45.7% of the patients.Conclusion:18F-FDG and 11C-PIB PET had a significant clinical impact in terms of change in diagnosis and treatment in patients with dementia in a developing country, similar to that reported in high-income countries. |
topic |
PET Alzheimer's amyloid dementia neuroimaging biomarkers |
url |
https://www.frontiersin.org/articles/10.3389/fneur.2021.630958/full |
work_keys_str_mv |
AT andresdamian clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT andresdamian clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT fabiolaportugal clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT nicolasniell clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT nicolasniell clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT adrianaquagliata clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT karinabayardo clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT omaralonso clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT omaralonso clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT rodolfoferrando clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry AT rodolfoferrando clinicalimpactofpetwith18ffdgand11cpibinpatientswithdementiainadevelopingcountry |
_version_ |
1721481795507060736 |